DE69631409D1 - Cathepsin-G-hemmende Aptamere - Google Patents

Cathepsin-G-hemmende Aptamere

Info

Publication number
DE69631409D1
DE69631409D1 DE69631409T DE69631409T DE69631409D1 DE 69631409 D1 DE69631409 D1 DE 69631409D1 DE 69631409 T DE69631409 T DE 69631409T DE 69631409 T DE69631409 T DE 69631409T DE 69631409 D1 DE69631409 D1 DE 69631409D1
Authority
DE
Germany
Prior art keywords
cathepsin
aptamers
inhibitory aptamers
nucleotides
inhibitory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631409T
Other languages
English (en)
Other versions
DE69631409T2 (de
Inventor
Franzpeter Bracht
Karsten Prof.Dr.Med. Schroer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gentium SRL
Original Assignee
Gentium SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium SRL filed Critical Gentium SRL
Priority to DE69631409T priority Critical patent/DE69631409T2/de
Application granted granted Critical
Publication of DE69631409D1 publication Critical patent/DE69631409D1/de
Publication of DE69631409T2 publication Critical patent/DE69631409T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
DE69631409T 1995-11-24 1996-11-21 Cathepsin-G-hemmende Aptamere Expired - Lifetime DE69631409T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE69631409T DE69631409T2 (de) 1995-11-24 1996-11-21 Cathepsin-G-hemmende Aptamere

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19543750A DE19543750C2 (de) 1995-11-24 1995-11-24 Cathepsin G inhibierende Aptamere
DE19543750 1995-11-24
DE69631409T DE69631409T2 (de) 1995-11-24 1996-11-21 Cathepsin-G-hemmende Aptamere

Publications (2)

Publication Number Publication Date
DE69631409D1 true DE69631409D1 (de) 2004-03-04
DE69631409T2 DE69631409T2 (de) 2004-12-02

Family

ID=7778263

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19543750A Expired - Fee Related DE19543750C2 (de) 1995-11-24 1995-11-24 Cathepsin G inhibierende Aptamere
DE69631409T Expired - Lifetime DE69631409T2 (de) 1995-11-24 1996-11-21 Cathepsin-G-hemmende Aptamere

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19543750A Expired - Fee Related DE19543750C2 (de) 1995-11-24 1995-11-24 Cathepsin G inhibierende Aptamere

Country Status (8)

Country Link
US (1) US5780449A (de)
EP (1) EP0775745B1 (de)
JP (1) JP4257939B2 (de)
AT (1) ATE258597T1 (de)
DE (2) DE19543750C2 (de)
DK (1) DK0775745T3 (de)
ES (1) ES2217297T3 (de)
PT (1) PT775745E (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682886B1 (en) * 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
AU3363399A (en) * 1998-03-27 1999-10-18 President And Fellows Of Harvard College Aptamer based bacterial inhibition systems (abbis)
US6458559B1 (en) 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
DE19916417A1 (de) * 1999-04-01 2000-10-19 Schering Ag Amyloidspezifisches Aptamer
EP1330544A4 (de) 2000-09-26 2005-04-06 Univ Duke Rna-aptamere und verfahren zu deren identifizierung
US7300922B2 (en) * 2001-05-25 2007-11-27 Duke University Modulators of pharmacological agents
US20040023415A1 (en) * 2002-03-05 2004-02-05 Konstantin Sokolov Biospecific contrast agents
WO2004001065A2 (en) 2002-06-24 2003-12-31 Cornell Research Foundation, Inc. Exhaustive selection or rna aptamers against complex targets
US20070003975A1 (en) * 2003-05-02 2007-01-04 Canon Kabushiki Kaisha Structured construct and producing method therefor
EP1493810A1 (de) * 2003-06-30 2005-01-05 Gentium S.p.A. Auf DNA-basierte Aptamere für Cathepsin G
JP4533044B2 (ja) * 2003-08-27 2010-08-25 キヤノン株式会社 センサ
DK1745062T3 (da) * 2004-04-22 2014-08-11 Regado Biosciences Inc Forbedrede modulatorer af koagulationsfaktorer
CA2567156A1 (en) * 2004-05-17 2006-07-20 Cambrios Technology Corp. Biofabrication of transistors including field effect transistors
EP2268664B1 (de) * 2007-12-03 2017-05-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Doc1-zusammensetzungen und verfahren zur behandlung von krebs
US20100018674A1 (en) * 2008-07-22 2010-01-28 Donald John Enzinna Reservoir with moveable partition for quick recovery
JP7120531B2 (ja) * 2018-02-12 2022-08-17 アプタキュア セラピューティクス リミテッド スクレロスチンに対するアプタマー及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
US5290762A (en) * 1986-12-24 1994-03-01 John Lezdey Treatment of inflammation
US5612194A (en) * 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
WO1991019813A1 (en) * 1990-06-11 1991-12-26 The University Of Colorado Foundation, Inc. Nucleic acid ligands
AU1435492A (en) * 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
DE69229552T2 (de) * 1991-05-23 1999-12-23 Merrell Pharma Inc Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides

Also Published As

Publication number Publication date
DE19543750A1 (de) 1997-07-03
EP0775745B1 (de) 2004-01-28
DE19543750C2 (de) 1997-10-23
US5780449A (en) 1998-07-14
DE69631409T2 (de) 2004-12-02
JPH09216895A (ja) 1997-08-19
ES2217297T3 (es) 2004-11-01
JP4257939B2 (ja) 2009-04-30
PT775745E (pt) 2004-06-30
ATE258597T1 (de) 2004-02-15
EP0775745A2 (de) 1997-05-28
DK0775745T3 (da) 2004-06-01
EP0775745A3 (de) 1999-10-13

Similar Documents

Publication Publication Date Title
DE69631409D1 (de) Cathepsin-G-hemmende Aptamere
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
ATE460481T1 (de) Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
DE69934010D1 (de) Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
DK0785252T3 (da) Antisense-oligonukleotider mod den alfa-regulatoriske subunit af den cAMP-afhængige proteinkinase til behandling af cancer
EA200500487A1 (ru) Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
FI946201A0 (fi) Itsestabiloidut oligonukleotidit terapeuttisina aineina
FR2688140B1 (fr) Canule laparoscopique.
ATE412052T1 (de) Synthetische polynukleotide
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
DE69328025T2 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
ATE157370T1 (de) Oligonukleotide mit wirkung gegen das respiratorische synzytial virus
HUP9802423A2 (hu) Hiperproliferatív megbetegedések kombinált gyógyászati kezelése
BR9610848B8 (pt) Actinobacillus pleuropneumoniae (app) transgênico, composição de vacina e vetor biológico transgênico.
NO980296D0 (no) Forbedrede terapeutiske midler
DE69531459D1 (de) Elatase-inhibitoren
ATE160354T1 (de) Oligonukleotide mit anti-cytomegalovirus wirkung
ITTO940379A0 (it) Sequenze specifiche per il dna umano.
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
ITBO970602A0 (it) Apparecchiatura per trattamento di dialisi.
신동희 The Concept of Finding Aids
NL1001157A1 (nl) Zuiveringsinstallatie.
IT1284413B1 (it) Impianto trattamento r.s.u.
BR0016347A (pt) Oligonucleotìdios antisenso

Legal Events

Date Code Title Description
8364 No opposition during term of opposition